Free Trial

Venus Concept (VERO) Competitors

Venus Concept logo
$2.21 -0.08 (-3.49%)
Closing price 04:00 PM Eastern
Extended Trading
$2.21 +0.00 (+0.05%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VERO vs. CTCX, MHUA, LYRA, LFWD, CHEK, OSRH, PAVM, TNON, POAI, and INBS

Should you be buying Venus Concept stock or one of its competitors? The main competitors of Venus Concept include Carmell (CTCX), Meihua International Medical Technologies (MHUA), Lyra Therapeutics (LYRA), Lifeward (LFWD), Check-Cap (CHEK), OSR (OSRH), PAVmed (PAVM), Tenon Medical (TNON), Predictive Oncology (POAI), and Intelligent Bio Solutions (INBS). These companies are all part of the "medical equipment" industry.

Venus Concept vs. Its Competitors

Venus Concept (NASDAQ:VERO) and Carmell (NASDAQ:CTCX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Venus Concept has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500. Comparatively, Carmell has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.

In the previous week, Venus Concept's average media sentiment score of 0.00 equaled Carmell'saverage media sentiment score.

Company Overall Sentiment
Venus Concept Neutral
Carmell Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Venus Concept
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Carmell
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Carmell has a net margin of 0.00% compared to Venus Concept's net margin of -68.77%. Carmell's return on equity of -217.50% beat Venus Concept's return on equity.

Company Net Margins Return on Equity Return on Assets
Venus Concept-68.77% -871.77% -61.92%
Carmell N/A -217.50%-50.22%

87.4% of Venus Concept shares are owned by institutional investors. Comparatively, 24.2% of Carmell shares are owned by institutional investors. 28.0% of Venus Concept shares are owned by company insiders. Comparatively, 29.0% of Carmell shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Carmell has lower revenue, but higher earnings than Venus Concept.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Venus Concept$64.83M0.05-$47M-$50.78-0.04
Carmell$32.84K288.69-$15.44MN/AN/A

Summary

Carmell beats Venus Concept on 7 of the 10 factors compared between the two stocks.

Get Venus Concept News Delivered to You Automatically

Sign up to receive the latest news and ratings for VERO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VERO vs. The Competition

MetricVenus ConceptMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$3.26M$7.31B$6.18B$10.67B
Dividend YieldN/A1.14%5.72%4.86%
P/E Ratio-0.0427.2629.0927.12
Price / Sales0.0527.68584.14126.40
Price / CashN/A22.2737.1261.42
Price / Book0.515.2312.246.43
Net Income-$47M$178.09M$3.33B$276.63M
7 Day Performance-7.14%-1.70%-1.46%-2.60%
1 Month Performance-4.33%1.07%5.03%0.31%
1 Year Performance-65.64%0.77%61.45%30.63%

Venus Concept Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VERO
Venus Concept
N/A$2.21
-3.5%
N/A-55.1%$3.26M$64.83M-0.04410
CTCX
Carmell
N/A$0.62
-18.4%
N/A+10.1%$12.96M$32.84K0.0014Gap Down
MHUA
Meihua International Medical Technologies
1.553 of 5 stars
$0.41
+1.5%
N/A-66.2%$12.95M$96.90M0.00620News Coverage
LYRA
Lyra Therapeutics
2.7911 of 5 stars
$7.58
-4.3%
$100.00
+1,219.3%
-44.0%$12.43M$1.53M-0.2650
LFWD
Lifeward
1.7191 of 5 stars
$0.77
+2.5%
$9.00
+1,070.4%
-72.8%$12.07M$25.66M-0.2560Gap Up
CHEK
Check-Cap
0.5688 of 5 stars
$2.04
+6.6%
N/A+6.8%$11.91MN/A-0.6880Short Interest ↓
Gap Down
OSRH
OSR
N/A$0.54
-3.5%
N/AN/A$11.74MN/A0.00N/A
PAVM
PAVmed
4.5658 of 5 stars
$0.53
-5.5%
$20.00
+3,709.5%
-55.8%$11.51M$2.99M0.4590News Coverage
Short Interest ↓
Gap Down
High Trading Volume
TNON
Tenon Medical
1.1785 of 5 stars
$1.20
+6.7%
$5.50
+360.3%
-71.1%$10.58M$3.28M-0.048News Coverage
POAI
Predictive Oncology
0.3315 of 5 stars
$13.35
-0.9%
N/A-5.5%$10.15M$1.62M-4.3830Short Interest ↑
INBS
Intelligent Bio Solutions
0.2773 of 5 stars
$1.08
+0.9%
N/A-29.3%$9.81M$3.05M-0.5310Positive News
Analyst Downgrade

Related Companies and Tools


This page (NASDAQ:VERO) was last updated on 10/22/2025 by MarketBeat.com Staff
From Our Partners